Introducing the First non ELISA-based PSA Activity Assay Kit!

August 2016  |  Press Releases

Introducing the First non ELISA-based PSA Activity Assay Kit!


MILPITAS, Calif. - Aug. 16, 2016 - PRLog -- Prostate Specific Antigen (PSA) or Kallikrein-related peptidase3, is a serine protease that proteolyses Semenogelin I and Semenogelin II in seminal fluid and thus liquefying it. PSA is measured in male blood to determine and diagnose asymptomatic prostate cancer. PSA also shows antiangiogenic activity. The significance of the level of enzymatically active PSA is emerging in diagnosis and prognosis of prostate cancer. Growing number of evidence suggests that PSA plays an important role in prostate tumor growth, invasion and metastasis. Normally, PSA levels are determined using immune-techniques such as ELISA-based platforms. BioVision's unique PSA Activity Assay Kit utilizes the ability of active PSA to cleave a synthetic fluorogenic substrate to release a free fluorophore. This assay kit does not require antibodies and long incubation periods. It is simple, sensitive and can be used in a high-throughput format.

Key Features:

• Non-radioactive, Simple: fluorometric format
• Non-ELISA based assay
• Specific, homogeneous assays
• Convenient: minimal sample preparation, fast protocols (1hour)
• Cost-effective: 100 assays
• Measures active PSA

Please click here to get more information on this assay kit:

About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.